Daphnetin for vascular cognitive impairment without dementia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Participants are assigned to receive either oral Daphnetin capsules or a matching placebo daily for six months, with follow-up visits every three months. Cognitive change is measured primarily with the Vascular Dementia Assessment Scale–cognitive subscale (VADAS‑cog) at six months, and MoCA and CDR scores are used for screening and monitoring. The trial enrolls adults aged 50–80 who report persistent cognitive complaints and meet MoCA (18–25) and CDR criteria consistent with impairment but not dementia. Safety and tolerability are recorded throughout the treatment and follow‑up period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Be 50-80 years of age (both ends included)
2. Have a complaint of cognitive impairment involving memory and/or other cognitive domains that has persisted for at least 3 months
3. Have a cognitive level that is neither normal nor demented according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Criteria ( DSM-V criteria）, a Montreal Cognitive Assessment (MoCA scale) score \<26 and ≥18, and a Clinical Dementia Rating (CDR) scale score of ≥0.5 in at least one domain and an overall CDR score ≤1
4. Have a cognitive level that is neither normal nor demented according to DSM-V criteria, a MoCA scale score \<26 and ≥18, and a CDR scale score of ≥0.5 in at least one domain and an overall CDR score ≤1
5. Voluntarily participate in this study and sign an informed consent form.

Exclusion Criteria:

1. Previously diagnosed dementia; vascular cognitive impairment not associated with a condition other than dementia that may affect cognition
2. Acute stroke event within 6 months
3. Previously diagnosed hereditary or inflammatory small vessel disease
4. Presence of congenital mental retardation and severe neurological or psychiatric disorders
5. Illiteracy or severe visual or hearing impairment, severe aphasia, and other factors that may preclude cooperation with neuropsychological evaluation
6. Associated depression (Hamilton Depression Scale score ≥ 17), or other unrelated serious mental illness (schizophrenia, bipolar disorder, or delirium)
7. Combined severe cardiac, pulmonary, and renal insufficiency (creatinine \> 2.0 mg/dl or 177 μ mol/L), and severe hepatic impairment (aminotransferases more than 3 times normal)
8. Alcoholism, drug addiction, or ongoing use of medications that affect cognitive assessment, such as tranquilizers, sleeping pills, puberty pills, and cholinergics
9. Malignant tumors that have been clearly diagnosed, vital organ failure
10. Those with bleeding tendency after surgery
11. Pregnant and lactating women are prohibited
12. Severe hypertension (Systolic Blood Pressure(SBP)≥160mmHg and/or Diastolic Blood Pressure(DBP)≥110mmHg) is prohibited
13. Previous allergy or intolerance to the ingredients of Reserpine
14. The subject does not have a stable and reliable caregiver or the caregiver is unable to assist the subject in participating in the study
15. Patients who have participated in other interventional clinical studies within the last 3 months or are currently participating in other interventional clinical studies.

Where it's running

• Shenyang First People's Hospital
  Shenyang, Liaoning, China Recruiting

Study contacts

• Principal investigator: Yi Sui, MD PhD — The Fourth People's Hospital of Shenyang, China Medical University
• Study coordinator: Yi Sui, MD PhD
• Email: jakeyisui@icloud.com
• Phone: +86 24 86861329

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Best Care for Acute Stroke in General Wards

  A nurse-led program called BEST CARE ICTUS_HC is tested in hospitals without Stroke Units to see if it reduces stroke complications and helps recovery after an acute ischemic or hemorrhagic stroke.

  Recruiting University of Malaga · Antequera, Málaga and 3 other locations · NCT07627399

• Hybrid mirror-primed rehabilitation for unilateral stroke

  This trial will test whether adding enhanced mirror priming to conventional therapy helps adults who had a first-time one-sided stroke at least three months ago improve upper-arm movement.

  Recruiting I-Shou University · Kaohsiung City, Yanchao District · NCT07324278

• Intra-arterial clot-dissolving treatment for medium-vessel ischemic stroke

  The team will test whether giving tenecteplase directly into the artery helps adults with acute ischemic stroke caused by medium-vessel blockage or severe narrowing.

  Recruiting at 6 sites The Second Hospital of Anhui Medical University · Fuyang, Anhui and 5 other locations · NCT07185022

• Dimephosphon® for recovery after acute ischemic stroke.

  This trial will test whether Dimephosphon® given 24–72 hours after stroke onset helps adults with moderate acute ischemic stroke recover better than a placebo.

  Recruiting at 5 sites Phase 3 Tatchempharmpreparaty, JSC · Vsevolozhsk, Leningradskaya Oblast' and 5 other locations · NCT07167550

• How environmental pollutants relate to brain tumours, stroke, and Alzheimer's

  This study will see if exposure to environmental pollutants is linked to brain tumours, cerebrovascular disease, and Alzheimer dementia in consenting adults, particularly those treated by neurosurgery.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07140601

• Atorvastatin for primary intracerebral hemorrhage

  This trial will see if adding atorvastatin to usual care helps adults (18–80) who have a spontaneous intracerebral hemorrhage and are treated within 3–24 hours of symptom onset.

  Recruiting at 22 sites The Second Hospital of Anhui Medical University · Anqing, Anhui and 21 other locations · NCT07088250

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.